- Terns Pharmaceuticals press release ( NASDAQ: TERN ): Q3 GAAP EPS of -$0.44 beats by $0.07 .
- As of September 30, 2022, cash, cash equivalents and marketable securities were $187.3 million as compared with $166.0 million as of December 31, 2021.
- Based on its current operating plan, Terns expects these funds will be sufficient to support its planned operating expenses into 2025, including through the expected proof-of-concept clinical readouts for TERN-701, TERN-601 and TERN-501
For further details see:
Terns Pharmaceuticals GAAP EPS of -$0.44 beats by $0.07